Could This Tiny Biotech Rout Intercept In Liver Disease Drugs?

Tiny biotech CymaBay (CBAY) launched to a high not seen in a month Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept Pharmaceuticals (ICPT), which has struggled with its rival drug.

X

In midday trading on the stock market today, shares of CymaBay ramped up 10.8%, near 13.40, after earlier rocketing as much as 24.3%. Meanwhile, Intercept sank 6.5%, near 70.20. Biotech stocks collectively advanced 0.6%.

CymaBay is testing a drug called...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

CymaBay [+]    CBAY [+]    Intercept Pharmaceuticals [+]    ICPT [+]    Intercept [+]   

More #news: